The invention relates to methods of detection, capture, isolation and targeting of cancer cells for example circulating tumor cells (CTCs) using carbohydrate recognition domain of a lectin. The invention relates to methods of diagnosis, prognosis and treatment of cancer.

The present invention is directed to methods for using a plurality of particles comprising surfaces each independently comprising a capture moiety to isolate and characterize biomarkers (e.g., for obstructive sleep apnea).

Provided is a test method for identifying prostate cancer by analyzing a sugar chain modifying PSA in a specimen, and detecting an abundance of a multisialylated LacdiNAc structure, in particular Glycan ID: 7512, Glycan ID: 7603, Glycan ID: 7612, and/or Glycan ID: 7613. Furthermore, calculation of PSA G-index from relative abundance(s) of Glycan ID: 7512 and/or Glycan ID: 7603 enables detection of prostate cancer with good specificity even in a patient having a PSA value in a gray zone.

The present invention provides a glucose sensor having a glucose receptor containing a binding site of formula (I): ##STR00001##
wherein X, n, m and R.sub.1 are defined herein. Also provided is a glucose sensor molecule for use in such a glucose sensor, the glucose sensor molecule containing the binding site of formula (I). The binding site has been found to have particularly good selectivity for glucose.

The present invention relates to a process for the non-destructive determination of gender, developmental stage and/or viability of an avian embryo in an egg, comprising (a) detecting at least a first developmental marker compound selected from sugars and/or amino acids, precursors and metabolites thereof in an egg at a time period of from the beginning of the incubation of the egg until the hatching; (b) measuring the amount of the at least first detected developmental marker compound, and (c) comparing the amount to a base line established for male and female, developmental stage of the embryo, and/or alive and deceased or non-developed embryo, to determine whether the embryo is viable, male and/or female, and/or the developmental stage of the embryo.

A system can facilitate detection of 1, 5-anhydroglucitol (1, 5-AG) present in a saliva sample. The saliva sample can be placed in contact with a portion of a sensing device that includes a 1, 5-AG sensor. An indicator of a concentration of 1, 5-AG in the saliva sample can be detected by the 1, 5-AG sensor. The 1, 5-AG sensor can send the indicator to a computing device that includes a processing unit. The processing unit can execute instructions stored in non-transitory memory to receive the indicator; measure an amount of 1, 5-AG in the saliva sample based on the indicator; and provide an output related to the amount of 1, 5-AG in saliva sample. The amount of 1, 5-AG in the saliva sample can be used as a diagnostic property for a subject who produced the saliva sample.

Provided is a glycated protein sensor provided with: immobilized protease; immobilized ketoamine oxidase; and a hydrogen peroxide detection section.

The disclosure relates to methods of analyzing a post-translationally modified protein of interest using electrophoresis, the methods comprising deglycosylating the protein of interest after labeling.

A problem to be solved by the present invention is to provide an immunochromatographic test strip capable of avoiding so-called blank color development in an immunochromatographic test strip and enabling more accurate determination by an approach different from the prior arts.

The present invention provides an immunochromatographic test strip comprising: at least a sample application region, a development region, and a detection region in which an antibody is immobilized, wherein the detection region includes the antibody and one or more saccharides selected from the group consisting of a reductive monosaccharide and a reductive disaccharide.

There is provided a molecule comprising a chain of seven or more contiguous units of 4,6-dideoxy-4-acylamido-α-pyranose, each pair of units joined by a C.sub.1-C.sub.2 or a C.sub.1-C.sub.3 link, the chain having a terminal end and a reducing end, wherein the pyranose ring in the unit of the chain most distal from the reducing end is linked to a cap structure. The cap structure is not a 4,6-dideoxy-4-acylamido-α-pyranose. There are also provided vaccine compositions comprising the molecule and methods of vaccinating an animal NI against infection by a Brucella organism, including methods of distinguishing between a vaccinated and an infected animal. There are further provided novel methods of detecting the presence in a sample of an anti-Brucella antibody.